SWOG clinical trial number
S0331

A Phase II Trial of STI-571/Imatinib (Gleevec®) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)

62% Accrual
Accrual
62%
Closed
Phase
62% Accrual
Accrual
62%
Published
Abbreviated Title
STI-571/Imatinib/Merkel Cell Melanoma
Activated
10/01/2003
Closed
03/01/2007
Participants
NCORP, Members, Medical Oncologists, Pathologists, ECOG

Research committees

Melanoma

Treatment

STI-571/Imatinib

Other Clinical Trials

S2000
SWOG Clinical Trial Number
CTSU/EA6174
SWOG Clinical Trial Number